Abstract: The alloy contains, by weight, less than 0.05% of carbon, from 0.015% to 0.5% of silicon, from 0.4% to 1.4% of manganese, from 28% to 31.5% of chromium, from 8% to 12% of iron, from 2% to 7% of molybdenum, from 0% to 0.75% of aluminium, from 0% to 0.8% of titanium, from 0.6% to 2% in total of niobium and tantalum, the ratio of percentages of niobium plus tantalum and of silicon being at least 4, less than 0.04% of nitrogen, from 0.0008% to 0.0120% of zirconium, from 0.0010% to 0.0100% of boron, less than 0.01% of sulphur, less than 0.020% of phosphorus, less than 0.30% of copper, less than 0.15% of cobalt and less than 0.10% of tungsten, the remainder of the alloy, with the exception of unavoidable impurities of which the total content is at most 0.5%, consisting of nickel. The alloy is used, in particular, for the production of wires for the electro-gas welding of units or components of nuclear reactors and, more particularly, of pressurised water-cooled nuclear reactors.

Abstract: The alloy contains, by weight, less than 0.05% of carbon, from 0.015% to 0.5% of silicon, from 0.4% to 1.4% of manganese, from 28% to 31.5% of chromium, from 8% to 12% of iron, from 2% to 7% of molybdenum, from 0.05% to 0.75% of aluminium, from 0.1% to 0.8% of titanium, from 0.6% to 2% in total of niobium and tantalum, the ratio of percentages of niobium plus tantalum and of silicon being at least 4, less than 0.04% of nitrogen, from 0.0008% to 0.0120% of zirconium, from 0.0010% to 0.0100% of boron, less than 0.01% of sulphur, less than 0.020% of phosphorus, less than 0.30% of copper, less than 0.15% of cobalt and less than 0.10% of tungsten, the remainder of the alloy, with the exception of unavoidable impurities of which the total content is at most 0.5%, consisting of nickel. The alloy is used, in particular, for the production of wires for the electro-gas welding of units or components of nuclear reactors and, more particularly, of pressurised water-cooled nuclear reactors.

Abstract: The present invention relates to a class of 2-aminothiazoline derivatives of formula I: in which either R1 is a hydrogen atom or an alkyl radical and R2 is an alkyl, -alk-NH2, —CH2—R3, —CH2—S—R4 or phenyl radical substituted with a nitro or —NH—C(═NH)CH3 radical, or R1 is an alkyl radical and R2 is a hydrogen atom, R3 is a (3-6C) cycloalkyl, pyridyl, pyridyl N-oxide, thienyl, thiazolyl, imidazolyl, pyrazinyl, triazolyl or phenyl radical or a phenyl radical substituted with a nitro, hydroxy or carboxyl radical, R4 represents a pyridyl or pyridyl N-oxide radical, alk represents an alkylene radical, or pharmaceutically acceptable salts thereof, which are useful as inhibitors of inducible NO-synthase.

Abstract: A connector (1) includes a body (7) for connecting wires (4) of a quadriaxially twisted cable (2) with contacts (11) of said connector. The connector includes insulating parts (14, 24, 34) for receiving the twisted cable, the untwisted wires and also to allow connecting the untwisted wires with the contacts. The insulating parts include channels arranged such that the characteristic impedance of the cable in the region of the untwisted wires is held at the same level as the characteristic impedance of the twisted wires.

Abstract: The present invention relates to a class of 2-aminothiazoline derivatives of formula I: 1

Abstract: The present invention relates to the use of 2-aminothiazoline derivatives of formula I: 1

Abstract: The present invention relates to the use of 2-aminothiazoline derivatives of formula: in which either R1 is a hydrogen atom or an alkyl radical and R2 is an alkyl, -alk—NH2, —CH2—R3, —CH2—S—R4 or phenyl radical substituted with a nitro or —NH— C (═NH) CH3 radical, or R1 is an alkyl radical and R2 is a hydrogen atom, R3 is a (3-6C) cycloalkyl, pyridyl, pyridyl N-oxide, thienyl, thiazolyl, imidazolyl, pyrazinyl, triazolyl or phenyl radical or a phenyl radical substituted with a nitro, hydroxy or carboxyl radical, R4 represents a pyridyl or pyridyl N-oxide radical, alk represents an alkylene radical, or pharmaceutically acceptable salts thereof, as inhibitors of inducible NO-synthase.

Abstract: The present invention relates to pharmaceutical compositions containing, as active principle, a 4,5-dihydro-1,3-thiazol-2-ylamine derivative of formula (I): in which R represents an -alk-S-alk-Ar radical, a phenyl radical or a phenyl radical substituted with alkoxy or halogen, or to one of the pharmaceutically acceptable salts thereof, to the novel derivatives of formula (I) and to their preparation.

Abstract: A connector (1) includes a body (7) for connecting wires (4) of a quadriaxially twisted cable (2) with contacts (11) of said connector. The connector includes insulating parts (14, 24, 34) for receiving the twisted cable, the untwisted wires and also to allow connecting the untwisted wires with the contacts. The insulating parts include channels arranged such that the characteristic impedance of the cable in the region of the untwisted wires is held at the same level as the characteristic impedance of the twisted wires.

Abstract: The present invention relates to the use of 2-aminothiazoline derivatives of formula: 1

Abstract: The present invention relates to pharmaceutical compositions containing, as active principle, a 4,5-dihydro-1,3-thiazol-2-ylamine derivative of formula (I): 1

Abstract: This invention relates to the use of heterocyclic carboxamide compounds for preventing or reducing self-administration, by a human or animal patient, of a drug or a substance capable of giving rise to pharmacomania or to overuse. The preferred types of drugs or substances are nicotine, caffeine, benzodiazepines, narcotics, and hallucinogens.

Abstract: Thiazolidine derivatives of formula (I), in which R.sub.1, R.sub.2, R.sub.3, R.sub.4 and R.sub.5 are as defined in the specification. The invention also concerns the salts of these derivatives, the preparation thereof and drugs containing same.

Abstract: This invention relates to compounds of formula (I), in which R denotes a hydrogen atom or a methoxy radical. The invention also concerns the salts of said compounds, their racemic forms, their enantiomers, the preparation of said derivatives and drugs containing same.

Abstract: This invention relates to an optically active hydroquinine (amino-3 phenyl)-1 ethanesulfonate (form A), preparation thereof and its use as an intermediate in the preparation of cholecystokinine and gastrin antagonists.

Abstract: This invention relates to compositions of formula: ##STR1## and their salts, their preparation and the medicaments containing them.

Abstract: This invention relates to compounds having formula (I), ##STR1## wherein R.sub.1 is a hydrogen or halogen atom or an alkyl, alkoxy, alkylthio, nitro, hydroxy or cyano radical; R.sub.2 is an alkyl radical or a chain --CH(R.sub.5)--CO--R.sub.6 ; R.sub.3 is (a) a phenyl radical substituted by one or a plurality of substituents selected amongst the radicals -alk-SO.sub.3 H, -alk-PO.sub.3 H.sub.2, --CH.dbd.NOH, --CH--NO-alk-COOX, --S-alk-COOX, --SO-alk-COOX, --SO.sub.2 -alk-COOX, --CH.dbd.CH--COOX, -alk-CO--NHOH, --C(.dbd.NOH)--COOX, -alk-N(OH)--CO-alk,-alk-SO.sub.2 H, --CH.dbd.CH--SO.sub.3 H, --C(COOX).dbd.N--O-alk-COOX, tetrazolyalkyle or a group having a formula (I) or (b) a ring having the formula (A) ##STR2## wherein R.sub.9 is a radical .dbd.NOX, .dbd.NO-alk-COOX, .dbd.CH--COOX, -alk-COOX, -alk-SO.sub.2 H or -alk-S).sub.3 H, R.sub.10 is an oxygen or sulfur atom or a methylene or alkylimino radical and R.sub.11 is a methylene or ethylene radical, R.sub.

Abstract: This invention relates to levogyral isomers of alkylammonium (amino-3 phenyl)-1 ethanesulphonate derivatives of formula (I) in which R+ denotes a tetraalkylammonium or trialkylphenylalkylammonium residue. The invention also concerns the preparation and use of said derivatives.

Abstract: Compounds of formula: ##STR1## in which R.sub.1 represents a hydrogen atom, an alkyl or alkoxycarbonyl radical or a phenyl radical, optionally substituted,R.sub.2 represents an alkoxy, optionally substituted cycloalkyloxy, cycloalkylalkyloxy, phenylalkyloxy, polyfluoroalkyloxy or cinnamyloxy radical or a radical --NR.sub.5 R.sub.6,R.sub.3 represents a phenylamino radical in which the phenyl ring is optionally substituted, an optionally substituted phenyl radical or a naphthyl, indolyl or quinolyl radical,R.sub.4 represents a substituted phenyl radical,R.sub.5 and R.sub.6, which may be identical or different, represent a hydrogen atom or an alkyl, optionally substituted phenyl, indanyl, cycloalkylalkyl, cycloalkyl or phenylalkyl radical, or alternatively R.sub.5 and R.sub.6, together with the nitrogen atom to which they are attached, form a heterocycle, their preparation and medicinal products containing them.

Abstract: Compounds of formula: ##STR1## in which R.sub.1 represents a hydrogen atom or an alkyl, alkoxycarbonyl or an unsubstituted or substituted phenyl radical,R.sub.2 represents a hydrogen atom or an unsubstituted or substituted alkyl radical,R.sub.3 represents an alkyl, phenylalkyl, indanyl, cycloalkylalkyl or an unsubstituted or substituted phenyl radical, orR.sub.2 and R.sub.3 form a heterocycle together with the nitrogen atom to which they are attached, andR.sub.4 represents an unsubstituted or substituted phenyl radical, a naphthyl, indolyl or quinolyl radical or a phenylamino radical in which the phenyl ring is unsubstituted or substituted, their preparation and medicaments containing them.